Hypertension (Case 7)

Hypertension (Case 7)


Elie R. Chemaly MD, MSc and Michael Kim MD


Case: A 59-year-old African-American woman is referred by her primary physician. She has had a history of severe hypertension for 38 years. She complains of dizziness, occipital headaches with blurred vision, and palpitations correlated with high BP sometimes reaching 200 mm Hg systolic and 120 mm Hg diastolic. She also has claudication of the legs and thighs upon walking four street blocks. She has a history of thyroid disease and is presently hypothyroid. Her medications on presentation were valsartan/hydrochlorothiazide 320 mg/25 mg (one tablet daily in the morning), clonidine 0.3 mg (one tablet daily in the evening), verapamil SR 240 mg (one tablet twice a day), and levothyroxine 0.1 mg (one tablet daily). Although she takes her medications each day as directed, she confides to you that she is concerned that they are becoming increasingly difficult for her to afford on a limited budget. She has an extensive family history of hypertension, and her father died at the age of 57 years in his sleep. On examination she weighs 68 kg, her pulse is 60 bpm, and her BP is 148/88 mm Hg. Her examination is remarkable for bilateral femoral bruits.


Differential Diagnosis




















Essential hypertension


Obesity


Sleep apnea


Renovascular disease


Primary aldosteronism


Primary mineralocorticoid excess, other than primary aldosteronism


Alcohol and substance abuse


Pheochromocytoma


Cushing syndrome (glucocorticoid excess)


Iatrogenic hypertension


Primary (parenchymal) renal disease


Other endocrine disorders: hypothyroidism, hyperthyroidism, hyperparathyroidism, acromegaly


 


Speaking Intelligently



 


PATIENT CARE


Clinical Thinking


• The definition of hypertension is an operational definition, which means that a BP is considered to be in the hypertensive range when it requires treatment to lower it, not just when it is above the number considered to be normal, and such treatment is required when the benefit of therapy outweighs the risk of therapy. This explains the changes in the definition of hypertension over the course of the years, motivated by treatment availability and data on treatment benefit and treatment targets.


• The seventh report of the Joint National Committee (JNC 7), published in 2003, has issued those definitions.1 Based upon the average of two or more BP readings at each of two or more visits after an initial screen, the following classification is used:


Normal blood pressure: systolic less than 120 mm Hg and diastolic less than 80 mm Hg


Prehypertension: systolic 120 to 139 mm Hg or diastolic 80 to 89 mm Hg


Hypertension:


Stage 1: systolic 140 to 159 mm Hg or diastolic 90 to 99 mm Hg


Stage 2: systolic ≥160 mm Hg or diastolic ≥100 mm Hg


• It is not the same thing to have hypertension and to have a BP that is not normal. The normal BP definition comes from studies recognizing a continuous rise in the risk of hypertension complications starting at a BP over 110/75 mm Hg (mainly cardiovascular morbidity and mortality).


• These definitions apply to adults on no antihypertensive medications and who are not acutely ill. If there is a disparity in category between the systolic and diastolic pressures, the higher value determines the severity of the hypertension. The systolic pressure is the greater predictor of risk in patients over the age of 50 to 60 years. Also, systolic blood pressure (SBP) is measured more reliably than diastolic blood pressure (DBP) and classifies most patients. Isolated systolic hypertension is common in elderly patients; younger hypertensive patients tend to have elevations of both SBP and DBP. An isolated elevation of the DBP is much less common.


• I need to know if the patient, especially in the acute setting, is presenting with malignant hypertension, hypertensive emergency, or hypertensive urgency.


• If the patient is already receiving antihypertensive therapy, the diagnosis of hypertension is made. I need to assess the particular therapeutic goal for the BP of this patient, since BP treatment goals vary from patient to patient (see JNC 7 report1) and the appropriateness of the treatment.


• The decision to search for a secondary cause of hypertension and/or poor BP control is made on a case-by-case basis.


History


The history should search for precipitating or aggravating factors as well as an identifiable cause (secondary hypertension), establish the course of the disease, assess the extent of target organ damage, and look for other risk factors for cardiovascular disease.


• Duration and course of the disease


• Prior treatment, response, tolerance, and compliance. Noncompliance with treatment is an important cause of poor BP control.


• Medications, diet, and social history: Drugs that may aggravate or cause hypertension include sympathomimetics, steroids, NSAIDs, and estrogens; psychiatric medications causing a serotonin syndrome; cocaine and alcohol abuse. Withdrawal syndromes and rebound effects also need to be considered: alcohol, benzodiazepines, β-blockers, and clonidine.


• Family history


• Comorbidities, especially diabetes; diseases that can be secondary causes of hypertension (e.g., kidney disease); other cardiovascular risk factors (e.g., tobacco).


• Symptoms of sleep apnea: early-morning headaches, daytime somnolence, snoring, erratic sleep.


• Symptoms of severe hypertension, end-organ damage, or volume overload: epistaxis, headache, visual disturbances, neurologic deficits, dyspnea, chest pain, syncope, claudication.


• Symptoms suggestive of a secondary cause: headaches, sweating, tremor, tachycardia/palpitations, muscle weakness, and skin symptoms.


Physical Examination


Proper measurement of BP: Away from stressors, with an appropriate cuff size, use Korotkoff phase V for auscultatory DBP. Korotkoff phase V is when the sounds disappear; one can use phase IV when they muffle if they do not disappear until a BP of 0 mm Hg. SBP, measured by auscultation, can and should also be measured through the radial pulse: when the cuff is inflated above the SBP, the radial pulse disappears. This maneuver allows the assessment of auscultatory gap (a stiff artery that does not oscillate and leads to an auscultatory underestimation of SBP) and pseudo-hypertension (a stiff artery not compressed by the cuff; SBP is overestimated). In selected settings, BP should be measured in both arms (especially in the younger patient to assess for coarctation of the aorta). Measurements should be repeated at different visits, unless BP is markedly elevated, before treatment.


Vital signs, in particular heart rate in relationship to BP and treatments already taken. It may be important, especially in the acute setting, to know if the patient is febrile or hypoxic. Mental status is an important vital sign in the acute setting (hypertensive emergencies and urgencies).


General appearance: body fat, skin (cutaneous manifestations of endocrinopathies causing secondary hypertension).


Funduscopic examination to evaluate retinal complications.


Thyroid examination.


Cardiac auscultation (for murmurs and abnormal sounds: An S4 gallop may indicate the stiff left ventricle of hypertensive heart disease).


Vascular auscultation (carotid bruits, renal bruits, pulses): to assess atherosclerotic status and the presence of renal artery stenosis; the relationship between carotid artery disease, its treatment, and hypertension is not well understood.


Abdominal examination, especially of the aorta and the kidneys.


Neurologic examination, if applicable.


Tests for Consideration








































ECG, mainly to assess for complications (atrial fibrillation, myocardial ischemia, LVH). Tachycardia (or atrial fibrillation) in the setting of hypertension may point to a secondary cause as well.


$27


Glucose finger-stick to rule out hypoglycemia, pulse oximetry, arterial blood gas to rule out hypercapnia or hypoxia (in acute settings).


$5


Metabolic panel: serum creatinine and electrolytes, especially potassium and glucose. The kidney is a key organ in the pathology of hypertension (see causes and complications), renal function and electrolytes are affected by antihypertensive therapy, and some metabolic abnormalities are a clue to a secondary cause. Examples include hypokalemia (in mineralocorticoid excess) and new-onset diabetes in the setting of several causes of secondary hypertension (e.g., Cushing).


$12


Complete blood count including hemoglobin and hematocrit.
These abnormalities can be a clue to many life-threatening illnesses, some related to the hypertension. Besides, anemia can cause hyperdynamic circulation and polycythemia can cause hyperviscosity, and, in acute settings, thrombocytopenia can point to a microangiopathic condition associated with hypertension.


$11


Urinalysis and microalbumin/creatinine ratio in urine.


$10


Thyroid profile and other endocrine studies as indicated in the search for a secondary cause. Hypothyroidism is common in older women, has atypical presentations, and may worsen atherosclerosis and obesity; it is listed as a secondary cause of hypertension.


$24


Lipid profile to assess cardiovascular risk.


$19


Toxicology screen, especially when substance abuse is suspected.


$21


• Laboratory and imaging workup for secondary causes (see individual paragraphs).


 


Sleep studies if applicable.


$795


Ambulatory BP monitoring, when white coat hypertension or masked hypertension is suspected, to diagnose paroxysmal hypertension (i.e., pheochromocytoma), and to assess resistance to treatment.


$65


Echocardiography to assess LVH (end-organ damage) and if cardiac dysfunction is suspected.


$393







Clinical Entities Medical Knowledge
































Essential Hypertension (90% of Patients)



Essential hypertension accounts for 90% of the cases of hypertension. The pathogenesis of essential hypertension is poorly understood. In fact, it does not appear to be one disease so that, among the multiple processes involved in the development of hypertension, one particular process may dominate the pathophysiology in a particular patient or group of patients. Among the important factors involved in essential hypertension are increased activity of the sympathetic nervous system, increased activity of the renin-angiotensin-aldosterone system, increased sodium retention (concepts of low-renin hypertension and impaired pressure natriuresis), low nephron mass, increased stiffness of the aorta and central arteries (thought to explain isolated systolic hypertension in the elderly), genetic factors, diet (high sodium and probably also low potassium intake), and psychosocial factors (especially the white coat form of hypertension).


Hypertension (whether essential or secondary) can lead to multiple complications, and the treatment of hypertension (a disease that is generally asymptomatic) is directed toward the prevention of those complications: cardiovascular disease (ischemic stroke, ischemic heart disease, aortic dissection—all manifestations of atherosclerosis), left ventricular hypertrophy, heart failure, atrial fibrillation, intracerebral hemorrhage, hypertensive nephropathy (different types exist), and hypertensive retinopathy.


TP


Hypertension by itself is generally asymptomatic unless BP is markedly and acutely elevated (malignant hypertension). Patients may also present with symptoms related to end-organ damage from hypertension (see “complications” above). Symptoms in the acute setting include headache, epistaxis, visual disturbances and signs of encephalopathy, chest pain in cases of aortic dissection or myocardial ischemia, and dyspnea and signs of congestion in the setting of heart or kidney failure. Since an acute illness or intoxication can be the cause of acute severe hypertension, it is important to relate the elements in the particular context of the patient and draw cause-effect relationships. For example, a patient with marked hypertension and altered mental status may have a hypertensive encephalopathy or a primary neurologic disorder leading to the elevation of his or her BP.


Dx


BP elevation as described above without an evident secondary cause (see Secondary Hypertension discussion by etiology). More emphasis is placed today on ambulatory BP measurement, since it is more representative of the real BP load sustained by the body in the patient’s daily life than an office measurement. Ambulatory BP monitoring is necessary to diagnose “white coat hypertension” and “masked hypertension.”


The diagnostic workup, besides establishing hypertension, includes the search for a secondary cause (other than essential hypertension), the search for end-organ damage, and the evaluation of cardiovascular risk.


Tx


BP must be properly measured and hypertension diagnosed by repeated measurements over several visits.


• Lifestyle modifications are the first step. They include weight reduction, the “DASH” diet (increase fruits and vegetables and lower saturated and total fat), a low-sodium diet, exercise, and alcohol restriction.


• Drug monotherapy must be initiated at 140/90 mm Hg, and initial dual therapy may be needed above 160/100 mm Hg.

 

• Major categories of antihypertensive medications can be simply classified according to the British AB/CD algorithm. “A” designates ACE inhibitors and ARBs, to which we can add the new renin inhibitor aliskiren. “B” designates β-adrenergic blockers. “C” designates calcium channel blockers. “D” designates diuretics.


• Regardless of BP reading, certain antihypertensive medications (mainly those in the AB category) are indicated in patients with a variety of cardiovascular and renal diseases. These compelling indications must be addressed and the appropriate therapy prescribed. Examples include the use of ACE inhibitors and ARBs in heart failure and kidney disease, and the use of β-blockers in ischemic heart disease and heart failure.

 

• Goal BP is generally 140/90 mm Hg. It should be 130/80 mm Hg in the setting of diabetes, chronic renal failure with proteinuria, and also in patients with cardiovascular disease. The amount of BP reduction is the most important factor in the benefit of antihypertensive therapy. In the absence of other compelling indications, and if the side effect profile is acceptable, a thiazide diuretic is the first choice of monotherapy. If dual therapy is needed, the most recommended strategy is to add an ACE inhibitor or an ARB to the diuretic. Generally, a “synergistic” combination of two antihypertensives includes one drug from the AB group and one from the CD group. β-Blockers should not be used as the initial monotherapy for isolated, essential hypertension; this recommendation is based on available clinical trials comparing them to other drugs.

 

• Other categories of antihypertensive medications are less commonly used; they include vasodilators (hydralazine, minoxidil), α1-adrenergic blockers, and α2-adrenergic agonists. Some medications combine β- and α-adrenergic blockade (labetalol). Also, diuretics can be combined with potassium-sparing diuretics (e.g., amiloride, triamterene, or spironolactone). The addition of an aldosterone antagonist may improve BP control in resistant hypertension.

 

• β-Blocker and centrally acting antihypertensives may cause rebound effects if discontinued abruptly.


Hypertensive Crisis


• Hypertensive urgencies represent substantial elevations in BP (DBP >120 mm Hg) with progressive end-organ damage, and perioperative hypertension. They require BP reduction within hours.


• Hypertensive emergencies include accelerated hypertension (BP > 210/130 mm Hg) with headaches, blurred vision, or focal neurologic symptoms; and malignant hypertension (with papilledema). Immediate mean BP reduction by 20% to 25% is needed to prevent end-organ complications (mean BP can be calculated grossly as image SBP + image DBP but is best measured directly by integrating the BP waveform in the arterial line; automated BP cuff machines give mean BP directly).


• In hypertensive emergencies, parenteral antihypertensive therapy is required. Intensive care unit monitoring is required, and intra-arterial BP measurement may be required. Parenteral agents include fenoldopam, sodium nitroprusside (caution: can cause thiocyanate intoxication and methemoglobinemia), labetalol (drug of choice in pregnancy), nitroglycerin (mostly in the setting of myocardial ischemia/infarction), esmolol (a β-blocker), nicardipine (approved for postoperative hypertension), enalaprilat (an ACE inhibitor that may give marked hypotension in high-renin states), and hydralazine (a good choice during pregnancy).

 

• In all cases of treatment, avoid precipitous drops in BP that can cause brain hypoperfusion. The goal is a mean BP reduction of 20% to 25% or a target DBP < 110 mm Hg, and should be attained over minutes to hours. In hypertensive urgencies, BP lowering can even be more progressive. BP normalization should be accomplished over several days. The circulation needs to adjust its properties to maintain flow at lower BP.


• Aortic dissection is beyond the scope of this chapter but is related to hypertensive emergencies and requires parenteral antihypertensive therapy as well. See Cecil Essentials 13.


















Primary (Parenchymal) Renal Disease



Hypertension occurs in kidney disease, acute or chronic. It is usually seen in vascular or glomerular disease, but polycystic kidney disease also frequently results in hypertension.


In acute glomerular disease, hypertension is related to sodium and water retention.


In vascular disease, it is primarily the activation of the renin-angiotensin system in the ischemic kidney that causes hypertension.


In chronic kidney disease, hypertension is highly prevalent, and several mechanisms are involved: sodium and water retention, activation of the renin-angiotensin system, high sympathetic tone, endothelial dysfunction, high levels of parathyroid hormone, and arterial stiffening.


TP


Elevation of the serum creatinine with a glomerular filtration rate below 60 mL/min and/or proteinuria. Edema is characteristic of acute glomerulonephritis.


Dx


Serum BUN and creatinine with urinalysis make the positive diagnosis. Etiologies are numerous and outside the scope of this chapter. Hypertension may itself cause kidney disease (nephroangiosclerosis, which can be acute, malignant or chronic).


Tx


Treatment depends on the cause. Fluid removal by diuretics and dialysis is important in acute glomerulonephritis, while inhibition of the renin-angiotensin system is important in vascular causes. Aggressive treatment of hypertension is important in chronic kidney disease to reduce disease progression and cardiovascular risk. Goal BP is 130/80 mm Hg. The treatment of proteinuria is also essential.


ACE inhibitors and ARBs specifically reduce the progression of chronic kidney disease and are indicated to reduce proteinuria but can result in further decrease in glomerular filtration and hyperkalemia; thus, they need to be used carefully. Most ACE inhibitors are eliminated by the kidneys, but fosinopril is cleared by the liver. Keep in mind that a small (~30%) and limited elevation of the serum creatinine that stabilizes over 1–2 months when treating with ACE inhibitors or ARBs does not require treatment interruption but is a sign of treatment efficacy. Hyperkalemia can be managed with diuretics and/or kayexalate. Diuretics are needed to treat volume overload, and loop diuretics are needed if the glomerular filtration rate falls below 30 mL/min. See Cecil Essentials 13.


















Iatrogenic Hypertension



A number of prescribed or over-the-counter medications can cause or aggravate hypertension through different mechanisms.


• Oral contraceptives can elevate BP within the normal range or induce hypertension; the mechanism is poorly understood.


• NSAIDs secondary to inhibition of renal prostaglandin production, especially prostaglandin E2 and prostaglandin I2, with subsequent sodium and fluid retention.


• Licorice is discussed in the section on mineralocorticoid excess.


• Glucocorticoids are discussed in the section on Cushing syndrome.


• Erythropoietin-induced hypertension is multifactorial and involves not only increased blood viscosity from a rising hematocrit, but also changes in vascular reactivity.


• Cyclosporine causes renal vasoconstriction and sodium/water retention.


• Sympathomimetics and stimulants (enhance sympathetic tone).


• Certain herbal supplements (depending on the content).


TP


As in essential hypertension. Malignant hypertension can occur with oral contraceptives. Edema, renal failure, and hyperkalemia can occur with NSAIDs. In the case of erythropoietin, hypertensive encephalopathy can occur with rapid rise of BP.


Dx


The association is not automatic; it may be established only when discontinuation of the medication lowers the BP.


Tx


Discontinuation or dose reduction of the responsible agent is usually effective. In terms of analgesics, acetaminophen may be better than NSAIDs (although acetaminophen was also associated with hypertension). In terms of oral contraceptives, hypertension is rare but may be severe. In the case of erythropoietin, slowly increasing the hematocrit along with fluid removal and antihypertensive therapy is helpful. Antiplatelet agents may reduce the risk of erythropoietin-induced hypertension. In the setting of cyclosporine-induced hypertension, calcium channel blockers are the drugs of choice; diltiazem can be used and reduces cyclosporine metabolism, but the benefit on cyclosporine nephrotoxicity is unproven. See Cecil Essentials 13.


















Hypertension Secondary to Alcoholism and Substance Abuse



Alcohol: Reactive acute hypertension can occur during alcohol withdrawal, but chronic alcohol consumption, even if moderate, can lead to hypertension. The mechanism is not clear. Cocaine inhibits norepinephrine reuptake.


TP


Alcohol can lead to hypertension that may be treatment-resistant. Cocaine raises BP but usually presents with acute cardiovascular complications (myocardial infarction, arrhythmias, stroke, and also aortic dissection among other manifestations).


Dx


History, toxicology screen, other features of intoxication or abuse.


Tx


Abstinence and management of the (acute) complications of the intoxication. See Cecil Essentials 13, 135.


















Pheochromocytoma



Excess production of norepinephrine, epinephrine, or dopamine by a tumor usually located in the adrenal medulla (90%), but also anywhere along the sympathetic chain.


TP


Half of the patients have paroxysmal hypertension and most of the rest have “what appears to be essential hypertension.” Some patients are normotensive. There is a triad of symptoms: headache, sweating, and palpitations. Many other presentations are possible. Secondary diabetes and a cardiomyopathy may occur.


Dx


Diagnosis is established by measurement of 24-hour urine metanephrines and catecholamines. Plasma free metanephrines can also be measured; some authors consider them the test of choice (they are sensitive but less specific). Urinary VMA (vanillylmandelic acid) is specific but less sensitive. CT scan or MRI of the abdomen should follow to locate the tumor (usually intra-adrenal; if not, can still be intra-abdominal). If using CT scan with contrast, keep in mind that iodine contrast agents can precipitate a hypertensive crisis in the setting of a pheochromocytoma. MIBG scintigraphy can locate tumors not seen on CT or MRI; MIBG scintigraphy is also useful to locate metastases of a malignant pheochromocytoma. 111In-pentetreotide scintigraphy (Octreoscan), or total-body MRI, and PET scanning are other imaging options to locate extra-adrenal or multiple tumors.


A pheochromocytoma can occur in the setting of a multiple endocrine neoplasia (MEN) or a phacomatosis. Both types of syndromes bring associations of life-threatening diseases. Uncovering the association is a caveat when a pheochromocytoma is diagnosed.


Tx


Removal of the tumor after appropriate pre-operative medical preparation. Surgery is usually delayed until hypertension is controlled by a combination of α- and β-blockade; β-blockers should not be used until appropriate α-blockade is achieved. See Cecil Essentials 13, 67.


















Primary Aldosteronism and Other Mineralocorticoid Excess States



Aldosterone can be produced in excess by a tumor or a hyperplasia of the adrenal cortex. Less commonly, disorders of the synthesis of the steroid hormones can lead to the inappropriate accumulation of steroids (aldosterone or other metabolites or precursors of cortisol) that have mineralocorticoid effect. One situation is of interest: The deficiency in 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) that converts cortisol to cortisone in the renal tubule and prevents cortisol from having mineralocorticoid action, since this enzyme can be inhibited by the ingestion of licorice and both situations lead to apparent hypermineralocorticism.


TP


Hypertension with hypokalemia and metabolic alkalosis (usually spontaneous hypokalemia). However, (severe) hypertension alone can lead to the diagnosis, and hypokalemia is thought to be a late manifestation and is often absent in patients with primary aldosteronism.


Dx


Hypertension, unexplained hypokalemia, and metabolic alkalosis. Some patients have a normal serum potassium concentration. The next step is to measure plasma renin activity and serum aldosterone levels. Typically, in primary aldosteronism, renin is suppressed and aldosterone elevated with an aldosterone-to-renin ratio above 20 and often above 50. Imaging of the adrenal glands follows to search for the adenoma, and adrenal vein sampling to demonstrate asymmetric secretion of aldosterone may be needed either if imaging is equivocal or if surgical removal of an adenoma is considered. If both renin and aldosterone are suppressed, then the hypermineralocorticism is not aldosterone-dependent. Glucocorticoid-remediable aldosteronism is one of the zebras in this category, and it requires genetic testing to demonstrate the hybrid gene in which aldosterone synthase is driven by adrenocorticotropic hormone (ACTH).


Tx


Removal of the tumor (especially if a carcinoma) and/or a mineralocorticoid receptor antagonist such as spironolactone or eplerenone. Dexamethasone suppression in the rare case of glucocorticoid-remediable aldosteronism. See Cecil Essentials 13, 67.


















Obesity



Mechanisms of hypertension in obesity are complex and not fully elucidated but include impaired sodium excretion, increased sympathetic nervous system activity, and activation of the renin-angiotensin-aldosterone system. Obesity is associated with insulin resistance and hyperinsulinism, which also has complex cardiovascular consequences; obesity is also a common cause of sleep apnea (see below).


TP


Same as essential hypertension. Obesity is also a factor in resistant hypertension.


Dx


Body mass index is above 30 kg/m2.


Tx


Weight reduction, diet, and exercise. Bariatric surgery in selected cases. See Cecil Essentials 60.


















Sleep Apnea



Increased sympathetic tone (reactive), lower nitric oxide availability.


TP


Hypertension in the setting of obesity, snoring, morning headaches, and daytime sleepiness.


Dx


Polysomnography can be ordered based on symptoms of sleep apnea.


Tx


Positive airway pressure or airway surgery. See Cecil Essentials 13, 20.


















Renovascular Disease



Renal artery stenosis is typically caused by atherosclerosis of the renal arteries in older patients or fibromuscular dysplasia (young women). There are numerous, less common other causes. One of those that deserves attention is cholesterol embolus after an angiography, which can cause ischemic renal injury and initiate a pathophysiologic process similar to that of renal artery stenosis. A unilateral stenosis of a renal artery induces renin secretion downstream and activation of the renin-angiotensin system in the affected kidney. BP rises to restore perfusion of that kidney and the other kidney is subjected to higher perfusion pressure, which preserves overall sodium and water elimination. In the setting of bilateral renal artery stenosis, the pathophysiology is similar but hypervolemia can occur, since pressure natriuresis is impaired.


TP


Hypertension is usually severe. It can be early in onset. Refractory hypertension, worsening hypertension in the setting of preexisting essential hypertension, reduced or worsening renal function, especially if renal function worsening follows treatment with an ACE inhibitor or an ARB (the new renin inhibitor can theoretically also have that latter effect), abdominal bruit, asymmetric kidney size on imaging, and/or hypertension with flash pulmonary edema.


Dx


The diagnosis should be pursued only if correction of a possible stenosis is an option. Stenoses >70% are most likely to cause hypertension.


The best test is arteriography, but it is invasive. Noninvasive alternatives are less sensitive. They include MR angiography, CT angiography, and Doppler ultrasound.


MR angiography is less sensitive in patients with fibromuscular dysplasia and is best for proximal disease. It also has specificity issues, since it can exaggerate stenoses. The use of gadolinium is also problematic in the setting of renal dysfunction. CT angiography is also good for proximal disease but has the problem of nephrotoxic contrast. Doppler ultrasound is better at detecting bilateral disease but is time-consuming and operator-dependent.


If suspicion is high and the patient is high risk, noninvasive testing is not sufficient to rule out the disease and angiography may have to be considered.


The two main indications for testing are severe or progressive hypertension and ischemic renal failure. Angiography is a risky procedure (cholesterol emboli, contrast-induced renal injury).


Even if a stenosis is found, its clinical significance remains to be established. A number of tests can be used to determine its hemodynamic significance (e.g., renal vein sampling for renin). In this situation the benefit of correcting the stenosis can be predicted. There is also a role for captopril renography.


Tx


Renal artery revascularization may improve hypertension and/or renal function, but the benefit of stenosis correction may be difficult to establish in the individual patient. In the setting of fibromuscular dysplasia, angioplasty is almost always effective if not curative. See Cecil Essentials 13, 31.


















Cushing Syndrome and Glucocorticoid Excess



Primary mechanism involves overstimulation of the nonselective mineralocorticoid receptor by excess cortisol, but insulin resistance and sleep apnea are additional contributors.


TP


Cushingoid facies, central obesity, ecchymoses, and muscle weakness. Exogenous steroid administration is a key question to ask.


Dx


History of steroid ingestion is essential, since it is most often iatrogenic. Initial testing includes a 24-hour urine cortisol or dexamethasone suppression test. If positive, more advanced testing is needed to establish if the syndrome is adrenal (ACTH-independent) or ACTH-dependent (may be pituitary or ectopic ACTH or ectopic corticotropin-releasing factor [CRF]).


Tx


A mineralocorticoid receptor antagonist should be the best antihypertensive therapy. Otherwise, removal of the tumor producing ACTH or cortisol (or CRF) is the definitive treatment. See Cecil Essentials 13, 67.


















Other Endocrine Diseases



• Hypothyroidism: increased peripheral vascular resistance.


• Hyperthyroidism: hyperdynamic circulation (high cardiac output and oxygen consumption with decreased peripheral vascular resistance).


• Hyperparathyroidism: The association with hypertension is not well established, but arterial stiffening is a likely complication.


TP


Symptoms are variable but often subtle for all three entities that are detected on more or less routine laboratory testing. However, note that pulse pressure is narrow in the setting of hypothyroidism and wide in the setting of hyperthyroidism.


Dx


Hypothyroidism is diagnosed by a typically elevated TSH and low T4 if peripheral in origin, or low to normal TSH and low T4 if pituitary in origin. In hyperthyroidism it is almost always peripheral in origin, so a low TSH is characteristic (other situations are very rare). Hyperparathyroidism comes with hypercalcemia, hypophosphatemia, and high parathyroid hormone concentrations. Further workup is needed to determine the etiology. Individual situations are often complex in terms of thyroid and parathyroid disease, and their discussion is beyond the scope of this chapter. MEN should be looked for in the setting of hyperparathyroidism, since hypertension may be due to an associated adrenal or pituitary tumor.


Tx


Varies according to the entity. BP responds variably to the correction of the endocrine disorder. See Cecil Essentials 66, 74.


Oct 3, 2016 | Posted by in MANUAL THERAPIST | Comments Off on Hypertension (Case 7)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access